The Safety and Tolerability Profile of Vilazodone, A Novel Antidepressant for the Treatment of Major Depressive Disorder.

CONCLUSION: Vilazodone 40 mg/day was well tolerated during short- and long-term MDD treatment in these trials. Safety profiles associated with 8- and 52-week exposure were consistent.
PMID: 27738360 [PubMed - in process]

Source: Psychopharmacology Bulletin - October 18, 2016 Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research